prinomastat + temozolomide

prinomastat + temozolomide is an experimental combination of two small molecule agents intended for antineoplastic therapy, primarily targeting malignant gliomas. **Temozolomide** is an oral alkylating agent used for the treatment of glioblastoma multiforme and refractory anaplastic astrocytoma, functioning by methylating guanine bases in DNA and causing DNA damage that leads to tumor cell apoptosis[1][2]. **Prinomastat** is a matrix metalloproteinase (MMP) inhibitor designed to block tumor-associated MMPs such as MMP-2, MMP-9, and MMP-14, enzymes involved in extracellular matrix remodeling and tumor invasion. While temozolomide is approved and widely used in brain tumors, prinomastat is an investigational agent and has mainly been studied in clinical trials as a potential adjunct to inhibit tumor invasiveness and resistance. The combination is being investigated to synergize tumor cell killing (temozolomide) with decreased tumor invasiveness and metastatic potential (prinomastat).

Brand names

Temomedac

Other names

prinomastattemozolomide